[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ideaya Biosciences Inc (IDYA)

Ideaya Biosciences Inc (IDYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,495,252
  • Shares Outstanding, K 87,861
  • Annual Sales, $ 218,710 K
  • Annual Income, $ -113,700 K
  • EBIT $ -183 M
  • EBITDA $ -189 M
  • 60-Month Beta -0.05
  • Price/Sales 11.20
  • Price/Cash Flow N/A
  • Price/Book 2.71

Options Overview Details

View History
  • Implied Volatility 119.93% (+52.42%)
  • Historical Volatility 32.85%
  • IV Percentile 78%
  • IV Rank 46.38%
  • IV High 198.61% on 03/19/26
  • IV Low 51.87% on 07/21/25
  • Expected Move (DTE 14) 0.75 (2.63%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 1,135
  • Volume Avg (30-Day) 210
  • Put/Call OI Ratio 1.27
  • Today's Open Interest 6,329
  • Open Int (30-Day) 21,572
  • Expected Range 27.65 to 29.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.22
  • Number of Estimates 3
  • High Estimate $-1.15
  • Low Estimate $-1.28
  • Prior Year $-0.88
  • Growth Rate Est. (year over year) -38.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.66 +2.68%
on 05/12/26
29.97 -5.24%
on 05/27/26
+0.21 (+0.74%)
since 05/01/26
3-Month
27.66 +2.68%
on 05/12/26
38.10 -25.46%
on 04/13/26
-5.91 (-17.23%)
since 03/03/26
52-Week
20.45 +38.84%
on 06/05/25
39.28 -27.70%
on 01/07/26
+6.76 (+31.24%)
since 06/03/25

Most Recent Stories

More News
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

SOUTH SAN FRANCISCO, Calif. , June 3, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

IDYA : 28.40 (+1.90%)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , May 29, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

IDYA : 28.40 (+1.90%)
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit

IDEAYA Biosciences (NASDAQ:IDYA) executives highlighted recent clinical progress across the company’s oncology pipeline during a fireside chat at TD Cowen’s seventh annual Oncology Innovation Summit,...

IDYA : 28.40 (+1.90%)
IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , May 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

IDYA : 28.40 (+1.90%)
IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing

IDEAYA Biosciences (NASDAQ:IDYA) Chief Executive Yujiro Hata said the precision oncology company is preparing for a busy 2026, led by regulatory and clinical milestones for darovasertib in metastatic uveal...

IDYA : 28.40 (+1.90%)
IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data

IDEAYA Biosciences (NASDAQ:IDYA) said its lead oncology program remains on track for a regulatory submission after reporting positive top-line data in first-line metastatic melanoma, while also highlighting...

IDYA : 28.40 (+1.90%)
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif. , May 5, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial...

IDYA : 28.40 (+1.90%)
IDEAYA's Darovasertib Approval Assumption Now Collides With What Revenue Actually Looks Like—Or Doesn't

Barchart Research What to Expect from IDYA Earnings IDYA Generated May 4, 2026 Current Price $28.90 EPS Estimate $$-1.07 Consensus Rating Strong Buy Average Move 4.38% IDEAYA's Darovasertib Approval Assumption...

IDYA : 28.40 (+1.90%)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , May 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

IDYA : 28.40 (+1.90%)
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma

SOUTH SAN FRANCISCO, Calif. , April 21, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have been selected for a...

IDYA : 28.40 (+1.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

IDEAYA Biosciences Inc. is an oncology-focused precision medicine company. It focuses on the discovery and development of therapeutics for patients using molecular diagnostics. The company's product pipeline consists of IDE196, MAT2A, PARG, Pol-theta and WRN which are in clinical stage. IDEAYA Biosciences...

See More

Key Turning Points

3rd Resistance Point 29.79
2nd Resistance Point 29.21
1st Resistance Point 28.81
Last Price 28.40
1st Support Level 27.83
2nd Support Level 27.25
3rd Support Level 26.85

See More

52-Week High 39.28
Fibonacci 61.8% 32.09
Fibonacci 50% 29.87
Last Price 28.40
Fibonacci 38.2% 27.65
52-Week Low 20.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.